Clinical Trial

Adebelizumab Combined With Chemotherapy and Radiotherapy Treat ES-SCLC

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated November 9, 2023 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
To observe the efficacy and safety of adebelizumab combined with chemotherapy and sequential adebelizumab combined with radiotherapy in the treatment of newly diagnosed extensive small cell lung cancer.
Trial Details
NCT Number NCT06125041
Lead Sponsor Qianfoshan Hospital
Conditions Extensive Small Cell Lung Cancer
Enrollment 51 participants
Start Date 2023-10-30
Primary Completion 2026-07-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2023-11-09